TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15499519

Group type: EXPERIMENTAL
Intervention: Goldmann perimeter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colvard pupillometer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (scotopic)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (mesopic low)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (mesopic high)
Number of subjects: 100
Study: 11258044

Group type: EXPERIMENTAL
Intervention: Flaxin tablets 5 mg (test formulation)
Number of subjects: 23
Study: 9167863

Group type: EXPERIMENTAL
Intervention: One-session treatment for spider phobia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated spider phobics)
Number of subjects: 0
Study: 1396766

Group type: EXPERIMENTAL
Intervention: EIA using the purified 120 kDa protein
Number of subjects: 127

Group type: COMPARATOR
Intervention: EIA using whole cell sonicate of a single Helicobacter pylori strain
Number of subjects: 127

Group type: COMPARATOR
Intervention: Western immunoblot
Number of subjects: 127
Study: 2990350

Group type: EXPERIMENTAL
Intervention: MCNU and radiation therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: MCNU alone
Number of subjects: 71
Study: 30704266

Group type: EXPERIMENTAL
Intervention: Formoterol/budesonide inhalation (4·5 µg/80 µg, twice daily) plus intranasal budesonide 64 µg twice daily (group A)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intranasal cellulose powder (ICP) 250 µg thrice daily (group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intranasal placebo 250 µg thrice daily (group C)
Number of subjects: 121
Study: 28109045

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 26651419

Group type: EXPERIMENTAL
Intervention: Shorter storage red blood cell transfusions
Number of subjects: 31497

Group type: COMPARATOR
Intervention: Longer storage red blood cell transfusions
Number of subjects: 31497
Study: 25046279

Group type: EXPERIMENTAL
Intervention: SFC (250/50 μg twice daily) combined with TIO (18 μg once daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: TIO alone (18 μg once daily)
Number of subjects: 56
Study: 22799589

Group type: EXPERIMENTAL
Intervention: Boceprevir 400 mg single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg single dose (Day 1 and Day 4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 20600990

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.7 mmol/l) for 1 h
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal fasting glucose (5 mmol/l) for 1 h
Number of subjects: 17
Study: 17681023

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16129968

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 12403238

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (300 microg/day for 9-60 months)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no inhaled corticosteroids)
Number of subjects: 145
Study: 10464846

Group type: EXPERIMENTAL
Intervention: Oral bambuterol (20 mg nocte)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms b.i.d.)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Comparison of bambuterol and salmeterol
Number of subjects: 117
Study: 8545518

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2301751

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) 1 h before induction (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) on the evening before surgery and 1 h before induction (group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam (0.3 mg/kg) 1 h before induction (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) (group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 6989685

Group type: EXPERIMENTAL
Intervention: Oxamethacin (100 mg t.i.d.)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 339
Study: 31667606

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 3000
Study: 28946113

Group type: EXPERIMENTAL
Intervention: Textured insoles for one week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional insoles after one week
Number of subjects: 19
Study: 26284338

Group type: EXPERIMENTAL
Intervention: Taxane treatment (EC/T arm)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: CEF treatment (CEF arm)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: TLE3 positive tumors (TLE3+)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: TLE3 expression
Number of subjects: 1097
Study: 23694947

Group type: EXPERIMENTAL
Intervention: MCIc (converted to Alzheimer disease)
Number of subjects: 110

Group type: COMPARATOR
Intervention: MCInc (stable MCI)
Number of subjects: 110
Study: 21866329

Group type: EXPERIMENTAL
Intervention: Multimodal programme incorporating pool‐based exercise using deep water running (DWR) three times a week for an 8‐week period
Number of subjects: 44

Group type: COMPARATOR
Intervention: Leaflet containing advice and continued normal activities
Number of subjects: 44
Study: 19040689

Group type: EXPERIMENTAL
Intervention: Individualized education
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Individualized education with peak flow monitoring
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study: 17362223

Group type: EXPERIMENTAL
Intervention: Modified Instrument (ensemble format)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Instrument (interleafed format)
Number of subjects: 0
Study: 15142022

Group type: EXPERIMENTAL
Intervention: Cardiovascular training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 11578885

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol (Group P)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.3 microg/kg remifentanil (Group R)
Number of subjects: 106
Study: 9661868

Group type: EXPERIMENTAL
Intervention: Serum relaxin concentration measured by ELISA
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Hip instability assessment via anterior-dynamic ultrasound
Number of subjects: 2185
Study: 7841695

Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) of 0.5 s and expiratory time (TE) of 0.5 s at 60 breaths/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) > or = 0.5 s
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) of 1.0, 0.67, and 0.5 s with expiratory times (TE) of 1.0, 1.33, and 1.5 s at 30 breaths/min
Number of subjects: 25
Study: 2437967

Group type: EXPERIMENTAL
Intervention: Progesterone (25 mg vaginal suppositories twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Progesterone treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30737047

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Calorie restriction plus fish oil supplementation (CRF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Calorie restricted meal replacement (CRMR)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Calorie restricted meal replacement with fish oil supplementation (CRMRF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Hp 1-1 phenotype
Number of subjects: 151
Study: 30864188

Group type: EXPERIMENTAL
Intervention: Curcumin (1,500 mg daily for 10 weeks)
Number of subjects: 44
Study: 28697810

Group type: EXPERIMENTAL
Intervention: Nurse-delivered intimate partner violence screening, supportive care and referral intervention
Number of subjects: 0
Study: 25122587

Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program (MLWP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Body-Weight-Supported Treadmill Training (BWSTT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups (MLWP and BWSTT)
Number of subjects: 71
Study: 23138389

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurolysis of the stellate ganglion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Stellate ganglion blockade
Number of subjects: 67
Study: 21959800

Group type: EXPERIMENTAL
Intervention: Drug A (400mg Norfloxacin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drug B (400mg Norfloxacin)
Number of subjects: 18
Study: 18804915

Group type: EXPERIMENTAL
Intervention: Comprehensive Pain Rehabilitation Program (CPRP) with opioid withdrawal, 3-week duration
Number of subjects: 373

Group type: COMPARATOR
Intervention: Non-opioid group
Number of subjects: 373
Study: 15915407

Group type: EXPERIMENTAL
Intervention: Intravenous nesiritide
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 12777951

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg/daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10490862

Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casual Blood Pressure (CBP) measurements
Number of subjects: 0
Study: 8558222

Group type: EXPERIMENTAL
Intervention: Extensive screening including CT scans and bilateral bone marrow biopsies
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard adjuvant therapy with high-dose chemotherapy and autologous bone marrow support (ABMT)
Number of subjects: 44
Study: 2066763

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (PE)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 140
Study: 6134604

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol 10 mg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31116675

Group type: EXPERIMENTAL
Intervention: anti-PD-1/L1 antibody
Number of subjects: 1747
Study: 28790131

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) game
Number of subjects: 456

Group type: COMPARATOR
Intervention: Civics game
Number of subjects: 456
Study: 26116581

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (omega-3 PUFAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs and Aspirin
Number of subjects: 0
Study: 25483663

Group type: EXPERIMENTAL
Intervention: Palivizumab (monthly doses); mean levels in PICU-admitted subjects were 47.2 μg/mL, while non-PICU subjects had 98.7 μg/mL (P < 0.0001).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Palivizumab level at RSVH; levels ≥ 92 μg/mL showed no PICU admissions.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Palivizumab level; correlated with duration of RSVH, PICU stay, supplemental oxygen use, and mechanical ventilation use (P < 0.05).
Number of subjects: 48
Study: 20504097

Group type: EXPERIMENTAL
Intervention: Oral ERT (oestradiol hemihydrate 2 mg/day, Estrofem®)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transdermal ERT (oestradiol hemihydrate 0.1% gel 1.5 mg/day, Estreva®)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No hormone therapy (control)
Number of subjects: 45
Study: 19502990

Group type: EXPERIMENTAL
Intervention: Short-course HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV/sdNVP
Number of subjects: 0
Study: 18161260

Group type: EXPERIMENTAL
Intervention: Prophylactic clotting factor replacement therapy, cost USD 300,000 per patient per year, started after the first episode of joint bleeding early in life.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment started after the first episode of joint bleeding.
Number of subjects: 0
Study: 15321800

Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA (0.63, 1.26, and 2.52 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA (0.59, 1.19, and 2.38 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLA supplementation (both isomers)
Number of subjects: 0
Study: 11458439

Group type: EXPERIMENTAL
Intervention: Pulsair (P), DeVilbiss, Sunrise Medical
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oxytron (O), Weinmann
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DOC‐2000 (D), TransTracheal Inc.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous oxygen delivery (CONT)
Number of subjects: 17
Study: 9706245

Group type: EXPERIMENTAL
Intervention: Ganciclovir alone or in combination with foscarnet
Number of subjects: 7
Study: 8067225

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetaphan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study: 2646975

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soft drink control
Number of subjects: 0
Study: 4904162

Group type: EXPERIMENTAL
Intervention: 50 mg of sustained release phenformin capsules administered twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30501926

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesive
Number of subjects: 120

Group type: COMPARATOR
Intervention: Silk suture
Number of subjects: 120
Study: 29091726

Group type: EXPERIMENTAL
Intervention: Sanitation promotion
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Handwashing promotion
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 181
Study: 26022965

Group type: EXPERIMENTAL
Intervention: Daily PROactive instrument
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Clinical visit PROactive instrument
Number of subjects: 236
Study: 24326395

Group type: EXPERIMENTAL
Intervention: Intravenous 100 ng/ml ketamine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2 mg oral risperidone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine plus 2 mg oral risperidone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21508131

Group type: EXPERIMENTAL
Intervention: Amiloride (20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide (25 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intranasal amiloride-sensitive potential
Number of subjects: 16
Study: 18054465

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg single oral dose
Number of subjects: 12
Study: 16585301

Group type: EXPERIMENTAL
Intervention: Oral sildenafil (1 mg/kg every 6 hours)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12963195

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 10859628

Group type: EXPERIMENTAL
Intervention: Standard suctioning procedure applied by the researcher
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group suctioning procedure applied by nurses
Number of subjects: 0
Study: 10225743

Group type: EXPERIMENTAL
Intervention: Polymyxin B immobilized fiber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma or whole blood exchange
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration or hemodiafiltration
Number of subjects: 0
Study: 1534991

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 2580178

Group type: EXPERIMENTAL
Intervention: Captopril 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of captopril and hydrochlorothiazide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31238517

Group type: EXPERIMENTAL
Intervention: Multifaceted, tailored intervention including nutrition intake magnets at patient bedsides, multidisciplinary hospital staff training, and foodservice system changes.
Number of subjects: 207
Study: 27535752

Group type: EXPERIMENTAL
Intervention: Vitamin D3 600 IU
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 58
Study: 27234632

Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard Policy
Number of subjects: 117
Study: 24773395

Group type: EXPERIMENTAL
Intervention: Mouth-to-face-shield ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mouth-to-pocket-mask ventilation
Number of subjects: 30
Study: 22588333

Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Quixil)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Postoperative blood recovery and reinfusion (control group)
Number of subjects: 70
Study: 19485844

Group type: EXPERIMENTAL
Intervention: Prospective screening for the predisposing genetic marker for abacavir hypersensitivity reactions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17320744

Group type: EXPERIMENTAL
Intervention: Multi-slice computed tomography (MSCT)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 197
Study: 15223977

Group type: EXPERIMENTAL
Intervention: Magnesium chloride (MgCl2) 2.5 g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12003703

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antihypertensive treatment)
Number of subjects: 0
Study: 9823639

Group type: EXPERIMENTAL
Intervention: Two Redons (one subcutaneously and one subfascial)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Three Redons (conventional procedure)
Number of subjects: 158

Group type: COMPARATOR
Intervention: One drain (subcutaneously or subfascial)
Number of subjects: 158
Study: 7994795

Group type: EXPERIMENTAL
Intervention: Adriamycin alone (Group A)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) (Group B)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Adriamycin and oral 5-FU (Group C)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 331
Study: 2658615

Group type: EXPERIMENTAL
Intervention: Oculab BioPen
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ultrascan Digital B System IV
Number of subjects: 58
Study: 1094994

Group type: EXPERIMENTAL
Intervention: Chloramphenicol 0.5% ophthalmic solution
Number of subjects: 0
Study: 31619184

Group type: EXPERIMENTAL
Intervention: Medido medication dispenser
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study: 28108038

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 181
Study: 26178502

Group type: EXPERIMENTAL
Intervention: Immune nutrition group (containing essential fatty acids, omega‐3 fatty acids, energy 1.3 kcal/ml), n = 30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nutrition group (self‐made homogenized diet 1.2 kcal/ml), n = 30
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immune nutrition group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nutrition group
Number of subjects: 60
Study: 23795745

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 20
Study: 21459815

Group type: EXPERIMENTAL
Intervention: Short breastfeeding (4 months only)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Long breastfeeding (until the mother decided to stop)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Weaned children (after 4 months)
Number of subjects: 618
Study: 19358213

Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study: 16469155

Group type: EXPERIMENTAL
Intervention: Isolated soya protein 30 g daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Milk protein 30 g daily (Control)
Number of subjects: 26
Study: 15199083

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day for 9 days) with olanzapine (10 mg single dose on day 4)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day for 9 days) with clozapine (10 mg single dose on day 4)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Olanzapine alone (10 mg single dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clozapine alone (10 mg single dose)
Number of subjects: 21
Study: 11346244

Group type: EXPERIMENTAL
Intervention: Bundle-branch block (BBB) present
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: New appearance of bundle-branch block (n = 64)
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Bundle-branch block (n = 76)
Number of subjects: 1239